Results 101 to 110 of about 16,360 (195)

Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial

open access: yes, 2017
Objective To characterise patients with active SLE based on pretreatment gene expression-defined peripheral immune cell patterns and identify clusters enriched for potential responders to abatacept treatment.
Somnath Bandyopadhyay   +19 more
core   +1 more source

Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive

open access: yesAdvances in Rheumatology
Background The HLA-DRB1 shared epitope (SE) is a risk factor for the development of rheumatoid arthritis (RA) and the production of anti-citrullinated protein antibodies (ACPAs) in RA patients. Our objective was to examine the real-world effectiveness of
Leslie R. Harrold   +8 more
doaj   +1 more source

Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis

open access: yesCase Reports in Transplantation, 2016
Recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation is difficult to treat. Recently a series of four patients unresponsive to plasma exchange (PE) and rituximab, who were successfully treated with abatacept, has been reported.
Hannelore Sprenger-Mähr   +3 more
doaj   +1 more source

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations

open access: yesBiologics: Targets & Therapy, 2014
Alvin F Wells,1,2 Nicole Jodat,1 Michael Schiff3 1Rheumatology and Immunotherapy Center, Franklin, WI, USA; 2Duke University Medical Center, Durham, NC, USA; 3University of Colorado, School of Medicine, Denver, CO, USA Abstract: There are now more ...
Wells AF, Jodat N, Schiff M
doaj  

Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives

open access: yes, 2018
Ashley Noisette, Marc C Hochberg Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA Abstract: Psoriatic arthritis (PsA) is a heterogeneous disease with several clinical ...
Noisette A, Hochberg MC
core  

Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial

open access: yes, 2020
Background: Abatacept was well tolerated by patients with early diffuse cutaneous systemic sclerosis in a phase 2, double-blind randomised trial, with potential efficacy at 12 months. We report here the results of an open-label extension for 6 months. /
Singer, O   +31 more
core  

Costo efectividad de Abatacept en comparación con otras terapias biológicas para el tratamiento de la artritis reumatoide moderada a severamente activa en pacientes que han fallado al tratamiento con metotrexato en EsSalud para el año 2010

open access: yesActa Médica Peruana
Objetivo: Estimar la costo efectividad de Abatacept combinado con Metotrexato (MTX) en comparación a otras DARMEs biológicas, en combinación con MTX, en pacientes con AR moderada a severamente activa.
Felipe Becerra Rojas   +6 more
doaj  

Abatacept as treatment for monogenetic and refractory inflammatory disease

open access: yes
Abatacept is a potent anti-inflammatory drug. Its effectiveness and safety in the treatment of rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis has been well researched in randomized controlled trials.
Berghuis, D.   +28 more
core  

Characterization of a novel homozygous CTLA4 variant. [PDF]

open access: yesJ Hum Immun
McTaggart T   +10 more
europepmc   +1 more source

Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry

open access: yes
Objective: The aim of this study was to report the interim 5-year safety and effectiveness of abatacept in patients with JIA in the PRINTO/PRCSG registry.
Griffin T.   +189 more
core   +1 more source

Home - About - Disclaimer - Privacy